From Research at med.fsu.edu Fri Aug 2 10:14:38 2019 From: Research at med.fsu.edu (Med Research) Date: Fri, 2 Aug 2019 14:14:38 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190448005@FSUCOM128.med.ad.fsu.edu> NIA Program Project Applications (P01 Clinical Trial Optional) The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award. Standard dates apply. Expires May 26, 2022. Med-RA deadline to receive draft documents for September 25, 2019 deadline: September 12, 2019. Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. Due September 30, 2019; February 11, 2020; September 30, 2020; February 11, 2021; September 20, 2021; and February 11, 2022. Med-RA deadline to receive draft documents for September 2019 deadline: September 17, 2019. Palliative Care in Home and Community Settings (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these funding opportunities is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in these FOAs refers to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care. Standard dates apply. Expires September 8, 2022. Due October 5 and October 16. Med-RA deadline to receive draft documents for October R01 deadline: September 24 and R21 deadline: October 3, 2019. Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum. Standard dates apply. Expires September 08, 2022. Med-RA deadline to receive draft documents for October 16, 2019 deadline: October 3, 2019. Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional) This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application. Standard dates apply. Expires January 08, 2022. Med-RA deadline to receive draft documents for October 16, 2019 deadline: October 3, 2019. Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed) This FOA will use the NIH Resource-Related Research Project (R24) mechanism to facilitate the development of research networks to advance research on the basic biology of aging in health disparities. The infrastructure-building aspect of this FOA will be to establish collaborations for subsequent research on the biology of aging underlying health disparities. The intention is to provide a platform for discovery and pilot projects to establish feasibility of novel approaches to be used by these collaborations. For this FOA, the key human population feature of health disparities is accelerated aging. Due October 18, 2019 and October 19, 2020. Med-RA deadline to receive draft documents for October 2019 deadline: October 7, 2019. Implementation Research on Hypertension Control to Prevent Dementia and Cognitive Decline (R61 / R33 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials on dissemination and implementation of practical approaches to hypertension treatment and control strategies among older adults with multimorbidity in order to prevent sequelae, including mild cognitive impairment and dementia. The research will: (1) be designed to address practical hypertension treatment questions faced by older adults with multimorbidity and their clinicians, (2) include broad and diverse populations, and (3) be conducted in real-world settings. These trials are intended to produce results that can be directly adopted by healthcare systems for rapid translation. This FOA will support pilot research to test the feasibility of implementing care interventions (R61 phase) that, if successful, can transition to an R33 phase for implementation of large pragmatic trials. Due October 22, 2019. Med-RA deadline to receive draft documents: October 9, 2019. Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76) K76 (Clinical Trial Required) K76 (Independent Clinical Trial Not Allowed) These Funding Opportunity Announcements (FOAs) invite early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for these awards to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. NIA is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through these awards, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for these awards must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. Due October 22, 2019. Med-RA deadline to receive draft documents: October 9, 2019. Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Alzheimer's Disease (R21 / R01 Clinical Trial Not Allowed) R21 This Funding Opportunity Announcement (FOA) invites early stage innovative and exploratory research focusing on understanding the regulation of brain regional and cell type-specific protein dynamics in Alzheimer's disease (AD). In particular, this FOA seeks applications proposing to develop novel proteomic platforms and animal models to further understanding of the alteration of a single-cell neuronal cell proteome in the central nervous system during the course of aging and AD. R01 This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD. Due October 23, 2019. Med-RA deadline to receive draft documents: October 10, 2019. Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG's Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins. The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base. Due October 28, 2019. Med-RA deadline to receive draft documents: October 15, 2019. Microbiome and Aging: Impact on Health and Disease (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites projects focused on defining the factors that influence microbiome composition and functional characteristics during aging, understanding how the aging microbiome relates to the causes and pathophysiology of age-related chronic diseases, and development and testing of targeted interventions through diet, drugs, or live organisms. This FOA will accept basic mechanistic, preclinical studies in animal models and human studies leveraging existing human longitudinal cohorts. Due October 30, 2019. Med-RA deadline to receive draft documents: October 17, 2019. NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed) The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability. Due October 31, 2019; March 3, 2020; June 30, 2020; October 27, 2020; March 2, 2021; June 29, 2021; October 26, 2021; March 1, 2022; and June 28, 2022. Med-RA deadline to receive draft documents for October 31, 2019 deadline: October 21, 2019. Preclinical Screening for Natural Product Drug Interactions (Clinical Trial Not Allowed, R21) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that seek to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. These in vitro studies may include screening libraries of complex extracts and/or purified natural products in suitable medium to high throughput assays to identify potential interactions. They may also include isolation and identification of novel, or not commercially available, natural products within complex mixtures that exhibit pharmacokinetic interactions. This FOA is part of a larger investment from NCCIH that includes a U54 Center of Excellence for Natural Product Drug Interaction Research. It is expected that data generated in projects supported under this FOA will be uploaded and made publicly available through the data repository maintained by the U54 Center. Due November 1, 2019. Med-RA deadline to receive draft documents: October 21, 2019. Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months. Due November 1, 2019; December 2, 2019; January 2, 2020; February 3, 2020; March 2, 2020; April 1, 2020; May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021; June 1, 2021; July 1, 2021; August 2, 2021; September 1, 2021; October 1, 2021; November 1, 2021; December 1, 2021; January 3, 2022; February 1, 2022; March 1, 2022; April 1, 2022; May 2, 2022; June 1, 2022; July 1, 2022; August 1, 2022; September 1, 2022; and October 3, 2022. Med-RA deadline to receive draft documents for November 1, 2019 deadline: October 21, 2019. Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines. Due November 12, 2019. Med-RA deadline to receive draft documents: October 29, 2019. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 / R01 - Clinical Trials Not Allowed) R21 R01 The purpose of these funding opportunity announcements is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology. Due November 14, 2019. Med-RA deadline to receive draft documents: October 31, 2019. Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 / R01 - Clinical Trials Not Allowed) R21 R01 The purpose of these funding opportunity announcements is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology. Due November 14, 2019. Med-RA deadline to receive draft documents: October 31, 2019. NSF: Ecology and Evolution of Infectious Diseases (EEID) The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases. Due November 20, 2019. Med-RA deadline to receive draft documents: November 6, 2019. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Aug 8 16:50:00 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 8 Aug 2019 20:50:00 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01904491B9@FSUCOM128.med.ad.fsu.edu> Concern Foundation: Conquer Cancer Now Award The Concern Foundation helps to bridge the gap that currently exists in the scientific research community by supporting promising early career scientists and providing critically-needed "seed" money for innovative research projects. To advance this mission, the foundation is inviting Letters of Intent for its Conquer Cancer Now Award program. Through the program, grants of $60,000 a year for up to two years will be awarded to approximately twenty young cancer researchers in support of innovative research in the areas of cancer genetics, cancer biology, or cancer immunology. The foundation does not fund clinical trials, cancer epidemiology, or behavioral studies. To be eligible, applicants must be an independent investigator at the start of his/her scientific career (i.e., junior faculty) and at the level of assistant professor (or equivalent, with explanation). PIs must have been in their current position for at least one year at the time of submission of the LOI. Applications are accepted from institutions in the United States and abroad and U.S. citizenship is not a requirement. Letter of intent due September 5, 2019. Med-RA deadline to receive draft documents: August 22, 2019. NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) This Funding Opportunity Announcement invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: September 24, 2019. NHLBI Single-Site Investigator-Initiated Clinical Trials (R61 / R33 Clinical Trial Required) This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due October 11, 2019; February 11, 2020; June 10, 2020; October 14, 2020; February 11, 2021; June 10, 2021; October 14, 2021; February 11, 2022; and June 10, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: September 30, 2019. Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 and R21/R33 Clinical Trial Optional) R33 This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets. The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted). R21/R33 This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. This FOA provides support for up to two years (R21, milestone-driven exploratory phase) for preliminary, proof-of-concept studies, which is followed by up to three years of support (R33 phase) for further/expanded preclinical development of the candidate therapeutic. Applicants may request funds for the development of assays and other methodologies required for translational studies in the project budget for the R21 and/or R33 phases. Funding for the R33 phase will be contingent on successful completion of established milestones in the R21 phase. The development of non-pharmacological interventions is considered outside the scope of these FOAs. Applications that focus on Alzheimer's disease or its related dementias are also outside the scope of these announcements. Standard dates apply. Expires July 17, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: October 3, 2019. Mechanisms of Tolerance (R21 / R33 - Clinical Trial Required) This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Standard dates apply. Expires January 08, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: October 3, 2019. Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 / U01 Clinical Trials Optional) R01 U01 The purpose of these Funding Opportunity Announcements (FOAs) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 / U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from these FOAs are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, these FOAs aim to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery. Due November 20, 2019. Med-RA deadline to receive draft documents: November 6, 2019. Catalyst Award In Diabetes, Endocrinology and Metabolic Diseases (DP1 Clinical Trial Not Allowed) The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere. Due December 3, 2019. Med-RA deadline to receive draft documents: November 18, 2019. Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gu?rin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged. This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines, that go beyond what have traditionally been investigated in TB. Due January 14, 2020 and January 14, 2021. Med-RA deadline to receive draft documents for 2020 deadline: January 2, 2020. Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Gu?rin (BCG) or investigational TB vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supported under this FOA should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications are sought that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV. Due January 14, 2020; January 14, 2021; and January 14, 2022. Med-RA deadline to receive draft documents for 2020 deadline: January 2, 2020. Lipid Signaling in Healthspan and Longevity Regulation (R01 Clinical Trial Not Allowed) To date, limited evidence suggests that regulation of lipid metabolism can modulate lifespan. This funding opportunity announcement aims to encourage innovative research programs designed to improve and expand our understanding of novel regulatory mechanisms governing lipid metabolism and signaling in the context of aging and age-associated conditions. Due February 3, 2020. Med-RA deadline to receive draft documents: January 21, 2020. Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 Clinical Trial Not Allowed / R01 Clinical Trial Optional) R21 R01 These Funding Opportunity Announcements (FOAs) invite applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD. The R21 supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. The R01 invites Stage 0 (basic research) or Stage I (intervention development/modification) clinical trials, in line with the NIH Stage Model. R21 due February 20, 2020 and July 22, 2020. Med-RA deadline to receive draft documents for 2020 deadline: February 10, 2020. R01 due February 7, 2020 and July 8, 2020. Med-RA deadline to receive draft documents for 2020 deadline: January 27, 2020. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Aug 23 08:14:56 2019 From: Research at med.fsu.edu (Med Research) Date: Fri, 23 Aug 2019 12:14:56 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01904493E0@FSUCOM128.med.ad.fsu.edu> Simons Foundation Autism Research Initiative: Winter 2020 Pilot Award Grants awarded through this RFA are intended to provide early support for exploratory ideas, particularly those with novel hypotheses for autism. Appropriate projects for this mechanism include those considered higher risk with less assurance of ultimate impact, but with the potential for transformative results. Investigators new to the field of autism are encouraged to apply for these awards. The total budget of a Pilot Award is $300,000 or less, including 20 percent indirect costs, over a period of up to two (2) years. Due September 13, 2019. Med-RA deadline to receive draft documents: September 3. American Psychological Foundation: Bruce and Jane Walsh Grant in Memory of John Holland The Bruce and Jane Walsh Grant in Memory of John Holland supports scientific, scholarly or applied research and/or educational activities investigating how personality, culture and environment influence work behavior and health (mental and physical). Preference will be given to early career psychologists (ten years or less postdoctoral), and pilot projects that, if successful, would be strong candidates for support from major federal and foundation funding agencies, and "demonstration projects" that promise to generalize broadly to similar settings in other geographical areas and/or to other settings. $15,000 for 1-year projects. Due September 15, 2019. Med-RA deadline to receive draft documents: September 3. Scleroderma Foundation: New and Established Investigator Grant Programs The Scleroderma Foundation seeks applications from promising new and established investigators both inside and outside the field of scleroderma research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to the disease. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources. New Investigator: 3 year projects; $50,000 per year; 8% IDC. Established Investigator: 2-year projects; $75,000 per year; 8% IDC. Due September 16, 2019. Med-RA deadline to receive draft documents: September 3. Foundation for Prader-Willi Research The Foundation for Prader-Willi Research was established in 2003 by a small group of parents who saw the need to foster research that would help their children with Prader-Willi syndrome lead more healthy and fulfilling lives. Today, FPWR addresses the many issues related to PWS, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders. To advance this mission, FBWR is inviting LOIs for its Grants Program. Through the program grants of up to $100,000 (with the possibility of a second year of funding) will be awarded in support of research that advances the understanding and treatment of Prader-Willi syndrome. Funding priorities identified by the foundation include understanding how loss of PWS-critical genes leads to the phenotype; neurobiology of hunger/feeding behavior in PWS; neurobiology of cognitive deficits, maladaptive behavior and mental illness in PWS; clinical care research: evaluation of existing drugs and interventions to improve health and quality of life in PWS; therapeutics development for PWS-genetic therapies; novel pharmaceuticals; and drug repurposing for PWS. Letter of intent due September 16, 2019. Med-RA deadline to receive draft documents: September 3. Robert Wood Johnson Foundation: Building Evidence on Nutrition Supports for Low-Income Families with Young Children The purpose of this funding opportunity is to support action-oriented research that advances health equity, builds the knowledge base, and informs policymaking to increase access to nutrition supports and reduce nutrition disparities. (RWJF is supporting research on the two other policy areas addressed in the research agenda-access to income supports and ECE-through separate calls for proposals.) Evidence generated through funded projects should inform practice and policy and guide practitioners and policymakers (federal, state, and local) in setting priorities and allocating resources. The Foundation is particularly interested in research on several federal nutrition programs that serve low-income families with young children and have the potential to help address nutritional disparities. They include the following: * The Supplemental Nutrition Assistance Program (SNAP), which provides benefits to supplement household resources for purchasing food; * The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), which provides benefits redeemable for specific foods, nutrition education, and breastfeeding support; and * The Child and Adult Care Food Program (CACFP), which provides subsidies for meals and snacks served by child-care centers and family day-care homes. Research on other federal, state, and local nutrition programs may also be relevant to this opportunity, to the extent that they benefit or target families with young children from birth to age 8. Brief proposals due September 24, 2019. Med-RA deadline to receive draft documents: September 11. NIDA Program Project Grant Applications (P01 Clinical Trial Optional) This Funding Opportunity Announcement announces the availability of support for collaborative research by multidisciplinary teams that is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for September 2019 deadline: September 12. American Academy of Neurology: Robert W. Katzman, MD, Clinical Research Training Scholarship in Alzheimer's and Dementia Research The American Academy of Neurology (AAN) strives to promote the highest quality patient-centered neurologic care and enhance member career satisfaction. To that end, and in collaboration with the Alzheimer's Association and the American Brain Foundation, AAN is inviting applications for the Robert W. Katzman, MD, Clinical Research Training Scholarship in Alzheimer's and Dementia Research. Through the award, a single award of $65,000 per year for two years plus a $10,000 annual stipend will be awarded to a young investigator in support of clinical research on Alzheimer's or a related dementia. For the purpose of this scholarship, research is defined as "patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurologic disease." Priority areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, diagnostic tests after clinical trials in phase 1, and health services and outcomes research. Disease-related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases. To be eligible, applicants must be an AAN member and must have completed residency or a PhD no more than five years prior to the beginning of the award (July 1, 2020). If applicants have completed both their residency and a PhD, eligibility is based on when residency was completed. Due October 1, 2019. Med-RA deadline to receive draft documents: September 18. Robert Wood Johnson Foundation: Advancing Equity, Diversity, and Inclusion in Policy and Law Research--for Early Career Investigators Policies for Action (P4A), a signature research program of the Robert Wood Johnson Foundation, is issuing a special call for proposals (CFP) to advance health equity by actively seeking new and diverse perspectives from the policy research field. This opportunity is designed to support researchers from multiple disciplines to better understand and find solutions that will promote health equity and foster action on policies and laws that ensure all people in America can attain and preserve good health and well-being. This opportunity will support early career researchers from underrepresented and historically disadvantaged backgrounds to: * Engage in career development activities and mentorship that will enhance their research capacity; * Develop a research project that examines existing policies or policy changes that can influence population health, well-being, and equity; * Produce and translate timely research results; and * Collaborate with other researchers to create a healthier, more equitable future for all people in America. P4A will provide support and training for up to six investigators. Two of these six will be researchers located in and conducting research within the state of New Jersey. Letter of intent due October 2, 2019. Med-RA deadline to receive draft documents: September 19. Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 / R01 Clinical Trial Optional) R21 R01 These FOAs encourage the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies. Due October 9, 2019; June 10, 2020; October 14, 2020; June 9, 2021; October 13, 2021; and June 8, 2022. Med-RA deadline to receive draft documents: September 26. Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 / R01 Clinical Trial Optional) R21 R01 Through these Funding Opportunity Announcements, the National Cancer Institute announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies. October 9, 2019; June 10, 2020; October 14, 2020; June 9, 2021; October 13, 2021; and June 8, 2022. Med-RA deadline to receive draft documents: September 26. Circadian Patterns of Gene Expression Associated with Disease (R01 - Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to identify abnormalities in circadian-ordered gene expression to improve our understanding of disease phenotypes, etiology, risk stratification, resilience, and therapeutic management in diseases. Due October 7, 2019. Med-RA deadline to receive draft documents: September 24. Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 / R21 Clinical Trial Not Allowed) R03 R21 The purpose of these Funding Opportunity Announcements is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: October 3. Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 - Clinical Trial Required) The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications will be required to include plans for project management, participant recruitment and retention , performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples of the source stem cell and clinical-grade stem cell-derived product for in-depth and independent characterization through the RM Innovation Catalyst (see description in Section I). Due to the complex nature of requirements in this FOA (e.g., 1:1 matching funds, resource sharing), applicants are strongly encouraged to communicate with the appropriate NIH Scientific/Research Contact and review online Frequently Asked Questions (FAQs) prior to submitting an application. Staff will be able to advise applicants in determining if their research meets the requirements and objectives of this FOA. Due October 18, 2019. Med-RA deadline to receive draft documents: October 7. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: